Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abdala ST
- Development stage
- Unknown
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Abdala ST is a recombinant protein subunit vaccine developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba for the prevention of COVID-19. The vaccine is based on the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein, which is expressed in the yeast *Pichia pastoris*. The "ST" designation refers to the "Sin Tiomersal" (thimerosal-free) formulation, developed to accommodate individuals with hypersensitivity to the preservative. It is typically administered as a three-dose intramuscular regimen and is adjuvanted with aluminum hydroxide. Abdala ST has received emergency use authorization and full regulatory approval in Cuba and several other nations, including Vietnam and Venezuela.
- Brand names
- Abdala
- Other names
- Abdala Sin TiomersalAbdala thimerosal-free
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)Angiotensin-converting enzyme 2 (ACE2)–Spike receptor-binding domain (RBD) protein–protein interface
Beyond the preview
Go deeper on Abdala ST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abdala ST.